Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324

PURPOSE: Non–small-cell lung cancer (NSCLC) commonly expresses the epidermal growth factor receptor (EGFR), which is associated with poor clinical outcome. Cetuximab is a chimerized monoclonal antibody that targets the EGFR and, in preclinical models, it demonstrates radiosensitization properties. W...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Blumenschein, George R., Paulus, Rebecca, Curran, Walter J., Robert, Francisco, Fossella, Frank, Werner-Wasik, Maria, Herbst, Roy S., Doescher, Philip O., Choy, Hak, Komaki, Ritsuko
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107747/
https://ncbi.nlm.nih.gov/pubmed/21555682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.7875
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados